EGF Theramed Health (TMED) AI Stock Analysis

• Market Cap: C$1.10M
• Dividend Yield: N/A
• Average Volume (3M): 2.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: N/A
• EPS Growth: -15.84%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Healthcare Information Services
• EPS (TTM): >-0.01
• Shares Outstanding: 11,616,665
• 10 Day Avg. Volume: 2,695
• 30 Day Avg. Volume: 2,638
• PEG Ratio: 0.26
• Price to Book (P/B): -0.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -29.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 19 Underperform
• Price Target: ―

EGF Theramed Health's overall stock score is very low, primarily due to its severe financial challenges, including negative income, balance sheet instability, and poor cash flow management. Technical indicators suggest weak stock momentum, and valuation metrics are unappealing due to the company's ongoing losses. These factors collectively contribute to a high-risk profile for potential investors.

EGF Theramed Health Business Overview & Revenue Model

Company Description

EGF Theramed Health Corp. provides psychedelic drugs for the treatment of mental health. It offers psychedelics for the treatment of conditions, such as treatment-resistant depression, anxiety, PTSD, and depression. The company was incorporated in 2011 and is headquartered in Vancouver, Canada.

How the Company Makes Money

EGF Theramed Health (TMED) generates revenue through the development and commercialization of genomic and regenerative health therapies. Key revenue streams include the sale of proprietary health products and therapies, as well as offering specialized healthcare services. The company may also engage in partnerships with research institutions or other healthcare entities to co-develop new treatments, which can provide additional revenue through licensing agreements or joint ventures. Strategic collaborations and advancements in their product offerings contribute significantly to their earnings.

EGF Theramed Health Financial Statement Overview

Summary

EGF Theramed Health is experiencing severe financial difficulties, evidenced by zero revenue, ongoing losses, negative equity, and challenging cash flow management. The company faces significant risks due to high leverage and a lack of income generation, necessitating urgent strategic changes to improve financial stability.

Income Statement

The company has consistently reported zero revenue over the past years, indicating a complete lack of income generation. Both EBIT and Net Income have remained negative, reflecting ongoing operational losses. The absence of revenue growth and persistent losses severely impact the financial health.

Balance Sheet

The company exhibits a highly leveraged balance sheet with negative stockholders' equity, indicating insolvency. The debt-to-equity ratio is not meaningful due to negative equity. This suggests significant financial instability and high financial risk.

Cash Flow

Free cash flow remains negative, although slightly improved in recent periods. Operating cash flow consistently trails net income, indicating cash management issues. The cash flow situation reflects ongoing financial strain, though there is some support from financing activities.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	―	-176.36K
EBITDA	-221.34K	-238.64K	-568.50K	-1.35M	-677.89K	-21.26M
Net Income	-262.99K	-269.25K	-623.00K	-1.69M	-968.71K	-20.40M
Balance Sheet
Total Assets	36.09K	214.41K	193.69K	178.67K	1.20M	510.45K
Cash, Cash Equivalents and Short-Term Investments	20.17K	10.01K	11.72K	15.23K	702.63K	363.76K
Total Debt	1.50M	1.47M	1.34M	1.22M	1.12M	1.58M
Total Liabilities	2.98M	2.92M	2.67M	2.51M	2.41M	2.55M
Stockholders Equity	-1.55M	-1.34M	-1.14M	-1.02M	91.48K	-503.81K
Cash Flow
Free Cash Flow	-182.92K	-134.71K	-576.01K	-993.42K	-783.76K	-2.43M
Operating Cash Flow	-182.93K	-134.71K	-576.01K	-993.42K	-783.76K	-1.71M
Investing Cash Flow	0.00	0.00	0.00	0.00	410.43K	-894.47K
Financing Cash Flow	-45.75K	133.00K	572.50K	306.02K	712.20K	2.83M

EGF Theramed Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TMED, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.08, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 66.64 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:TMED.

EGF Theramed Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	AU$2.48B	3.20	-57.47%	2.71%	36.73%	13.67%
CHS	44 Neutral	C$9.51M	―	2.18%	―	-7.15%	97.22%
NEWU	42 Neutral	C$866.33K	―	56.02%	―	-36.40%	-21.88%
NDAT	39 Underperform	C$619.91K	―	-80.60%	―	-92.67%	20.42%
TMED	19 Underperform	C$1.10M	―	20.09%	―	―	-15.84%
CGNSF	―	$654.35K	―		―	―	―
NARA	29 Underperform	C$15.45M	―	213.49%	―	―	71.97%